Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Toyota Motor Corp (TM) Price & Performance

Incyte CorporationTrade
Toyota Motor CorpTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Toyota Motor Corp — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while Toyota Motor Corp trades at $189.04 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 9.1× Incyte Corporation's market cap, and Toyota Motor Corp pays a 3.32% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYTM
Market Cap
$24.65B$223.57B
Sector
HealthConsumer Cyclical
52-Week High
$129.93$248.29
52-Week Low
$81.61$166.50
Enterprise Value
$20.15B$417.39B
Dividend Yield
3.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.

The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.

Toyota Motor Corp

Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.

Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Toyota Motor Corp

Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.

Read more on TM